Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma - Outcomes From a Multinational Register Study
Latest Information Update: 07 Aug 2023
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary) ; Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Allergic rhinitis; Asthma
- Focus Therapeutic Use
- Sponsors ALK-Abello
- 31 Jul 2023 Planned number of patients changed from 40000 to 49844.
- 31 Jul 2023 Planned End Date changed from 30 Jun 2024 to 1 Jun 2024.
- 31 Jul 2023 Planned primary completion date changed from 30 Jun 2024 to 1 Jun 2024.